Immune co-signaling to treat cancer

Margaret K. Callahan, Jedd D. Wolchok, James P Allison, Padmanee Sharma

Research output: Chapter in Book/Report/Conference proceedingChapter

3 Scopus citations


The past two decades have been marked by a growing understanding of the co-stimulatory and co-inhibitory pathways that are critical to the generation of an effective, well-regulated immune response. Capitalizing on an increasingly nuanced appreciation for the role that these molecules play in anti-tumor immune responses, a diversity of novel therapies to treat human cancers are being explored. The ground-breaking success of anti-CTLA-4 therapy in the treatment of advanced melanoma has set the stage for the clinical development of agents targeting a diversity of co-stimulatory and co-inhibitory molecules. Herein, we review the co-signaling molecules that regulate T cell activation with a focus on their potential role(s) in anti-tumor immune responses. Where available, pre-clinical and clinical studies evaluating the anti-tumor activity of agents targeting these molecules are presented.

Original languageEnglish (US)
Title of host publicationCancer Immunotherapy
Subtitle of host publicationParadigms, Practice and Promise
PublisherSpringer New York
Number of pages70
ISBN (Electronic)9781461447320
ISBN (Print)1461447313, 9781461447313
StatePublished - May 1 2013


ASJC Scopus subject areas

  • Medicine(all)

Cite this

Callahan, M. K., Wolchok, J. D., Allison, J. P., & Sharma, P. (2013). Immune co-signaling to treat cancer. In Cancer Immunotherapy: Paradigms, Practice and Promise (Vol. 9781461447320, pp. 211-280). Springer New York.